Jeffrey Bacha is the President & CEO of Del Mar Pharmaceuticals, a company which he co-founded in 2010 to rapidly develop and commercialize proven cancer therapies in new indications where patients are failing modern targeted or biologic treatments. Mr. Bacha is a seasoned executive leader with nearly twenty years of life sciences experience in the areas of operations, strategy and finance. His background includes successful public and private company building from both a start-up and turn around perspective; establishing and leading thriving management and technical teams; and raising capital in both the public and private markets. Mr. Bacha serves as a Director of Sernova Corp. (TSX-V: SVA), was the founding CEO of Inimex Pharmaceuticals Inc and co-founder of XBiotech and Urigen Holdings Inc. He has also held positions as and Exec. VP Corporate Affairs & Chief Operating Officer at Clera Inc., VP Corporate Development at Inflazyme Pharmaceuticals Ltd. (TSE: IZP) and Senior Manager & Director at KPMG Health Ventures. Mr. Bacha has been recognized as a “Top 40 under 40” executive by Business in Vancouver magazine and is the former Chair of the Greater Vancouver Economic Council. Mr. Bacha is active in his community through volunteerism with the Leukemia & Lymphoma Society’s Team in Training (TNT) program. He has been running socially and competitively for a number of years. He originally got involved with TNT in 2005 and continues to participate in honor of his Father who succumbed to mantle cell lymphoma. By participating in TNT events he is continually amazed by the quality of the people who participate and the sheer passion that emanates from individuals and teams raising literally tens of millions of dollars each year for research against these devastating cancers. Beyond business and running, he enjoys all of the outdoor activities Vancouver has to offer. He also serves as Chairman on the Board of Covenant House Vancouver, an organization dedicated to assisting at-risk and homeless youth to re-enter society.